Related references
Note: Only part of the references are listed.Experimental HER2-targeted therapies for biliary tract cancer
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
Ole A. Mandrup et al.
COMMUNICATIONS BIOLOGY (2021)
The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance
Maryann Tabasinezhad et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies
Kaijie He et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2019)
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
Jesus Garcia-Foncillas et al.
FRONTIERS IN ONCOLOGY (2019)
68PA novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
M M Hou et al.
ANNALS OF ONCOLOGY (2019)
Relevance of Anti-Galactose-α-1, 3-Galactose Antibodies in the Era of Monoclonal Antibodies
Ankit Mangla et al.
JOURNAL OF ONCOLOGY PRACTICE (2019)
Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
Atrish Bagchi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer
Ying Zhang et al.
MOLECULAR CANCER (2018)
Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
ONCOLOGY (2018)
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Zaima Mazorra et al.
SEMINARS IN ONCOLOGY (2018)
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Tobias Grabe et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Dongsheng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS
Sheng Liu et al.
PLOS ONE (2017)
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy
Laura Lattanzio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Necitumumab: First Global Approval
Karly P. Garnock-Jones
DRUGS (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Bispecific T-cell engagers for cancer immunotherapy
Amelia M. Huehls et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Li Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence
Pablo Conesa-Zamora et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
Martin H. Cohen et al.
ONCOLOGIST (2013)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
Mareike Voigt et al.
NEOPLASIA (2012)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains
Jeroen J. Lammerts van Bueren et al.
NATURE BIOTECHNOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
Panitumumab A Review of its Use in Metastatic Colorectal Cancer
Gillian M. Keating
DRUGS (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Mammalian meat-induced anaphylaxis: Clinical relevance of anti-galactose-α-1,3-galactose IgE confirmed by means of skin tests to cetuximab
Sandrine Jacquenet et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family
H. Michael Shepard et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer
Andres Upez-Albaitero et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2007)
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Hideharu Kimura et al.
CANCER SCIENCE (2007)
Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
Jun Qian et al.
ANALYTICAL BIOCHEMISTRY (2007)
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
G. Galizia et al.
ONCOGENE (2007)
Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats
Xiao Tang Yu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
FDA drug approval summary: Panitumumab (Vectibix (TM))
Ruthann M. Giusti et al.
ONCOLOGIST (2007)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Judit Anido et al.
EMBO JOURNAL (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
S Segaert et al.
ANNALS OF ONCOLOGY (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours
M Ng et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
KJ Busam et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Share Paper
